Together, we can transform the status quo for kidney disease treatment.

It is our duty to carefully evaluate the safety and efficacy of any of our investigational precision medicine product candidates. We believe that clinical trials are the best and most appropriate way to do that. The process is a collaborative effort, and we will work closely with researchers, physicians, clinical trial site teams, people living with kidney diseases and their families to conduct our studies efficiently and effectively. When successful, data from these studies form the basis of regulatory (i.e. U.S. Food and Drug Administration, European Medicine Agency, or other similar regulatory agencies) approvals, which ensure the most equitable and sustainable access to our precision medicines for the people who need them.

We know that people living with kidney diseases and their families are counting on us to potentially extend and improve their quality of life. Given this, we understand that some people living with kidney diseases and their families may be interested in accessing our investigational precision medicine product candidates prior to regulatory approval, and outside of the clinical trial setting, through an expanded access program (sometimes referred to as “early access” or “compassionate use”). Goldfinch Bio does not offer programs that allow access to our precision medicine product candidates prior to regulatory approval. For now, participating in a clinical trial is the only way to access our precision medicine product candidates.

More information about Goldfinch Bio’s current clinical trials is available above in the section titled “Information about our ongoing clinical trials.” If you have additional questions, please talk to your doctor or contact earlyaccessprogram@goldfinchbio.com. We plan to acknowledge receipt of requests sent to this email address within five business days.